Bluebird prices gene therapy at 1.575 million euros over five years
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
from Reuters: Health News https://reut.rs/2RgciEG
http://bit.ly/2zwRqiM
June 14, 2019
|
Labels:
health,
Reuters: Health News
|
This entry was posted on June 14, 2019
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.